Neutrophil to lymphocyte ratio in the pre-treatment phase of final-line chemotherapy predicts the outcome of patients with recurrent ovarian cancer

Nakamura,Keiichiro; Nagasaka,Takeshi; Nishida,Takeshi; Haruma,Tomoko; Ogawa,Chikako; Kusumoto,Tomoyuki; Seki,Noriko; Hiramatsu,Yuji

doi:10.3892/ol.2016.4513

Neutrophil to lymphocyte ratio in the pre-treatment phase of final-line chemotherapy predicts the outcome of patients with recurrent ovarian cancer

Authors:
- Keiichiro Nakamura
- Takeshi Nagasaka
- Takeshi Nishida
- Tomoko Haruma
- Chikako Ogawa
- Tomoyuki Kusumoto
- Noriko Seki
- Yuji Hiramatsu
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama 700‑8558, Japan, Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama 700‑8558, Japan
Published online on: May 4, 2016 https://doi.org/10.3892/ol.2016.4513
Pages: 3975-3981
Copyright: © Nakamura et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inflammation and tumor immunology are associated with prognosis in a variety of cancers. The aim of the present retrospective study was to identify associations between the neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), cancer antigen 125 (CA125) concentrations, tumor response, performance status (PS) and survival of patients that developed recurrent ovarian cancer subsequent to receiving chemotherapy. The NLR and PLR measured prior to fourth‑line chemotherapy were significantly increased compared with those measured prior to second‑line chemotherapy (P=0.029 and 0.049, respectively). By using receiver operating characteristic curves, the cut‑off values were determined for the NLR, PLR and CA125 levels that were measured during the pre‑treatment phase, which predicted the outcomes. According to univariate analyses, pre‑treatment NLR >3.91, PLR >299.0 and PS 2 were each significantly associated with poor outcomes (P=0.001, 0.005 and 0.021, respectively). According to multivariate analyses, only pre‑treatment NLR was associated with poor outcome (P=0.035). The present findings indicate that pre‑treatment NLR is an important predictor of prognosis in patients with ovarian cancer that experience recurrence following chemotherapy.

View Figures

View References

1.	Prat J: FIGO Committee on Gynecologic Oncology: Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 124:1–5. 2014. View Article : Google Scholar : PubMed/NCBI
2.	Cannistra SA: Cancer of the ovary. N Engl J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
3.	Clarke-Pearson DL: Clinical practice. Screening for ovarian cancer. N Engl J Med. 361:170–177. 2009. View Article : Google Scholar : PubMed/NCBI
4.	Covens A, Carey M, Bryson P, Verma S, Fung Kee, Fung M and Johnston M: Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol. 85:71–80. 2002. View Article : Google Scholar : PubMed/NCBI
5.	Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, et al: ICON and AGO Collaborators: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet. 361:2099–2106. 2003. View Article : Google Scholar : PubMed/NCBI
6.	Alberts DS, Liu PY, Wilczynski SP, Clouser MC, Lopez AM, Michelin DP, Lanzotti VJ and Markman M: Southwest Oncology Group: Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol. 108:90–94. 2008. View Article : Google Scholar : PubMed/NCBI
7.	O'Brien ME, Yau T, Coward J, Hughes S, Papadopoulos P, Popat S, Norton A and Ashley S: Time and chemotherapy treatment trends in the treatment of elderly patients (age>or=70 years) with non-small cell lung cancer. Clin Oncol (R Coll Radiol). 20:142–147. 2008. View Article : Google Scholar : PubMed/NCBI
8.	Kim A, Fall P and Wang D: Palliative care: Optimizing quality of life. J Am Osteopath Assoc. 105(Suppl 5): S9–S14. 2005.PubMed/NCBI
9.	Renouf D, Kennecke H and Gill S: Trends in chemotherapy utilization for colorectal cancer. Clin Colorectal Cancer. 7:386–389. 2008. View Article : Google Scholar : PubMed/NCBI
10.	Lee Y, Kim SH, Han JY, Kim HT, Yun T and Lee JS: Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. J Cancer Res Clin Oncol. 138:2009–2016. 2012. View Article : Google Scholar : PubMed/NCBI
11.	Balkwill F and Mantovani A: Inflammation and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
12.	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
13.	Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, et al: Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. J Natl Cancer Inst. 106:dju1242014. View Article : Google Scholar : PubMed/NCBI
14.	Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, Seruga B, Ocaña A, Tannock IF and Amir E: Prognostic role of platelet to lymphocyte ratio in solid tumors: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 23:1204–1212. 2014. View Article : Google Scholar : PubMed/NCBI
15.	Aliustaoglu M, Bilici A, Seker M, Dane F, Gocun M, Konya V, Ustaalioglu BB and Gumus M: The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer. Hepatogastroenterology. 57:640–645. 2010.PubMed/NCBI
16.	Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T and Widmann WD: Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 19:217–224. 2012. View Article : Google Scholar : PubMed/NCBI
17.	Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK and Vauthey JN: Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol. 16:614–622. 2009. View Article : Google Scholar : PubMed/NCBI
18.	Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P and Lim E: Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg. 137:425–428. 2009. View Article : Google Scholar : PubMed/NCBI
19.	Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y and Fukushima M: The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology. 73:215–220. 2007. View Article : Google Scholar : PubMed/NCBI
20.	Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, et al: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 309:883–887. 1983. View Article : Google Scholar : PubMed/NCBI
21.	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
22.	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
23.	Prommer E: Guidelines for the use of palliative chemotherapy. AAHPM Bulletin. 5:2–13. 2004.
24.	McIllmurray M: Symptom management. Oxford Textbook of Palliative Medicine. Doyle D, Hanks G, Cherny NI and Calman K: (3rd). (New York, NY). Oxford University Press. 229–239. 2004.
25.	Lin X, Li W, Lai J, Okazaki M, Sugimoto S, Yamamoto S, Wang X, Gelman AE, Kreisel D and Krupnick AS: Five-year update on the mouse model of orthotopic lung transplantation: Scientific uses, tricks of the trade, and tips for success. J Thorac Dis. 4:247–258. 2012.PubMed/NCBI
26.	Schreiber RD, Old LJ and Smyth MJ: Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science. 331:1565–1570. 2011. View Article : Google Scholar : PubMed/NCBI
27.	Jackson JR, Seed MP, Kircher CH, Willoughby DA and Winkler JD: The codependence of angiogenesis and chronic inflammation. FASEB J. 11:457–465. 1997.PubMed/NCBI
28.	McMillan DC, Canna K and McArdle CS: Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 90:215–219. 2003. View Article : Google Scholar : PubMed/NCBI
29.	Assoian RK and Sporn MB: Type beta transforming growth factor in human platetlets: Release during platelet degranulation and action on vascular smooth muscle cells. J Cell Biol. 102:1217–1223. 1986. View Article : Google Scholar : PubMed/NCBI
30.	Dubernard V, Arbeille BB, Lemesle MB and Legrand C: Evidence for an alpha-granular pool the cytoskeletal protein alpha-actinin in human platelets that redistributes with the adhesive glycoprotein thrombospondin-1 during the exocytotic process. Arterioscler Thromb Vasc Biol. 17:2293–2305. 1997. View Article : Google Scholar : PubMed/NCBI
31.	Kaplan KL, Broekman MJ, Chernoff A, Lesznik GR and Drillings M: Platelet alpha-granule proteins: Studies on release and subcellular localization. Blood. 53:604–618. 1979.PubMed/NCBI
32.	Qian X and Tuszynski GP: Expression of thrombospondin-1 in cancer: A role in tumor progression. Proc Soc Exp Biol Med. 212:199–207. 1996. View Article : Google Scholar : PubMed/NCBI
33.	Dabrow MB, Francesco MR, McBrearty FX and Caradonna S: The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol Oncol. 71:29–37. 1998. View Article : Google Scholar : PubMed/NCBI
34.	Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT and Lee K: Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 58:15–23. 2009. View Article : Google Scholar : PubMed/NCBI
35.	Asher V, Lee J, Innamaa A and Bali A: Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol. 13:499–503. 2011. View Article : Google Scholar : PubMed/NCBI
36.	Matsuyama R, Reddy S and Smith TJ: Why do patients choose chemotherapy near the end of life? A review of the prospective of those facing death from cancer. J Clin Oncol. 24:3490–3496. 2006. View Article : Google Scholar : PubMed/NCBI
37.	Keam B, Oh DY, Lee SH, Kim DW, Kim MR, Im SA, Kim TY, Bang YJ and Heo DS: Aggressiveness of cancer-care near the end-of-life in Korea. Jpn J Clin Oncol. 38:381–386. 2008. View Article : Google Scholar : PubMed/NCBI